Meeting
2022 ASCO Annual Meeting
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.
Authors
Dmitry Yu. Gvaldin
National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
Dmitry Yu. Gvaldin , Natalya N. Timoshkina , Larisa N. Vashchenko , Tatiana V. Ausheva , Aleksandr B. Sagakyants , Oksana G. Shulgina , Irina R. Dashkova , Emma E. Kechedzhieva , Liubov Yu Vladimirova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12077)
DOI
10.1200/JCO.2022.40.16_suppl.12077
Abstract #
12077
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.
First Author: Juan José Serrano Domingo
Poster
2022 ASCO Annual Meeting
SNP-SNP interactions and a 4-locus model for prediction the risk of anthracycline-mediated cardiotoxicity in patients with breast cancer.
First Author: Dmitry Yu. Gvaldin
Poster
2024 ASCO Annual Meeting
Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Dirk Arnold
Poster
2023 ASCO Annual Meeting
Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.
First Author: Shari Beth Goldfarb